Observational studyApplied biochemistry and biotechnology2026
Serum Exosomal Hsa_circ_0005692 as A Novel Biomarker for Colorectal Cancer Metastasis: A Retrospective Observational Study.
Observational study in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Background. Increasing evidence suggests that exosomal circular RNAs (circRNAs) could serve as promising novel biomarkers for colorectal cancer (CRC) detection. However, diagnostic potential of exosomal circRNAs in CRC metastasis remain largely underexplored. Methods. The differentially expressed circRNAs (DEcircRNAs) were screened through GSE159669 and GSE205643 datasets. Seventy patients with CRC and seventy age- and sex-matched healthy controls were retrospectively enrolled in this study. The expression of DEcircRNAs was validated in paired cancer and paracancerous tissues, as well as in serum and serum-derived exosomes by RT-qPCR. The clinical significance, prognostic, and diagnostic efficacy of DEcircRNAs were evaluated through chi-square test, Kaplan-Meier survival curves, Cox regression model analysis, and receiver operating characteristic curves. The effect of DEcircRNAs on CRC cell migration and invasion was assessed through wound healing and transwell assays with gain- and loss-of-function methods. Results. A total of six DEcircRNAs were identified, among which only hsa_circ_0005692 exhibited consistent upregulation in cancer tissues, serum, and serum-derived exosomes from patients with CRC. Increased exosomal hsa_circ_0005692 was positively associated with lymph node metastasis and distant metastasis. Patients with elevated levels of exosomal hsa_circ_0005692 exhibited lower overall survival and progression-free survival rates, and exosomal hsa_circ_0005692 was identified as an independent risk factor for poor overall survival. Notably, exosomal hsa_circ_0005692 showed superior diagnostic accuracy than its expression in tissues and serum counterparts in differentiating not only CRC patients from healthy controls, but also metastatic patients from non-metastatic patients. Moreover, hsa_circ_0005692 was found to facilitate CRC metastasis by promoting cell migration and invasion as well as epithelial-mesenchymal transition. Conclusion. This study provides preliminary evidence that serum exosomal hsa_circ_0005692 may serve as a potential biomarker for predicting metastasis in CRC patients, and functionally facilitates CRC metastasis. However, larger-scale confirmatory studies and external validation are still required to substantiate this conclusion.
Indexed as
Identifiers
41790367What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.